Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Naonori Harada is active.

Publication


Featured researches published by Naonori Harada.


Biology of Blood and Marrow Transplantation | 2016

High Incidence of Afebrile Bloodstream Infection Detected by Surveillance Blood Culture in Patients on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell Transplantation.

Kazuaki Kameda; Shun-ichi Kimura; Yu Akahoshi; Hirofumi Nakano; Naonori Harada; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Hideki Nakasone; Misato Kikuchi; Rie Yamazaki; Junya Kanda; Shinichi Kako; Aki Tanihara; Junji Nishida; Yoshinobu Kanda

Bloodstream infections (BSI) are still important complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients who are receiving corticosteroid therapy can develop BSI without fever. The utility of surveillance blood cultures in these situations is controversial. We retrospectively analyzed 74 patients who received a corticosteroid consisting of ≥.5 mg/kg prednisolone or equivalent after allo-SCT. In principle, we performed surveillance blood culture weekly for these patients. Sixteen patients (21.6%) developed definite BSI. In a multivariate analysis, a myeloablative conditioning regimen, high-risk disease status at allo-SCT, and the presence of a central venous catheter at the initiation of corticosteroid therapy were identified as independent significant risk factors for the development of definite BSI. At the first definite BSI episode, 7 patients (46.7%) were afebrile and diagnosed by surveillance blood culture. However, 6 of these 7 afebrile patients showed various signs that could be attributed to infection at the time of positive blood culture. In conclusion, patients receiving corticosteroid therapy after allo-SCT frequently develop afebrile BSI. Although surveillance blood culture might be beneficial in these situations, it also seems important to not miss the signs of BSI, even when patients are afebrile.


Clinical Transplantation | 2016

Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation

Yu Akahoshi; Shun-ichi Kimura; Hirofumi Nakano; Naonori Harada; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Hideki Nakasone; Misato Kikuchi; Rie Yamazaki; Junya Kanda; Shinichi Kako; Junji Nishida; Yoshinobu Kanda

Patients with hematological malignancies show a high prevalence of asymptomatic colonization with Clostridium difficile (CD colonization). Therefore, it is difficult to distinguish CD colonization with diarrhea induced by a conditioning regimen from true Clostridium difficile infection (CDI) in hematopoietic stem cell transplantation (HSCT) recipients. We retrospectively analyzed 308 consecutive patients who underwent a CD toxin A/B enzyme immunoassay test for diarrhea within 100 d after HSCT from November 2007 to May 2014. Thirty patients (9.7%) had positive CD toxin results, and 11 of these had positive results in subsequent tests after an initial negative result. Allogeneic HSCT, total body irradiation, stem cell source, acute leukemia, and the duration of neutropenia were significantly correlated with positive CD toxin results. In a logistic regression model, allogeneic HSCT was identified as a significant risk factor (odds ratio 18.6, p < 0.01). In an analysis limited to within 30 d after the conditioning regimen, the duration of neutropenia was the sole risk factor (odds ratio 10.4, p < 0.01). There were no distinctive clinical features for CDI, including the onset or duration of diarrhea. In conclusion, although CDI may be overdiagnosed in HSCT recipients, it is difficult to clinically distinguish between CDI and CD colonization.


European Journal of Radiology | 2015

A retrospective analysis of computed tomography findings in patients with pulmonary complications after allogeneic hematopoietic stem cell transplantation

Tomotaka Ugai; Kohei Hamamoto; Shun-ichi Kimura; Yu Akahoshi; Hirofumi Nakano; Naonori Harada; Kazuaki Kameda; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Hideki Nakasone; Misato Kikuchi; Rie Yamazaki; Tomohisa Okochi; Junya Kanda; Shinichi Kako; Osamu Tanaka; Yoshinobu Kanda

OBJECTIVE The purpose of this study was to review the high-resolution computed tomography (CT) findings in patients with pulmonary complications after allogeneic hematopoietic stem cell transplantation (HSCT), and to evaluate the relationship between CT findings and clinical outcomes. PATIENTS AND METHODS We collected the clinical data in 96 consecutive patients who underwent CT scan for pulmonary complications after allogeneic HSCT and analyzed the relationships among these clinical characteristics, CT findings and clinical responses. Radiologists who were blinded to clinical information evaluated the CT findings. RESULTS In multivariate analyses, the presence of chronic graft-versus-host disease (GVHD) and non-segmental multiple consolidations were significantly associated with a poor response to antimicrobial therapies, and the disease risk was significantly associated with a poor corticosteroid response. In addition, the existence of cavity formation and pleural effusion were significantly associated with a fatal prognosis. Twenty-five patients underwent bronchoscopic examination and 4 of them also underwent transbronchial lung biopsy (TBLB), but diagnostic information was not obtained in 15 patients. There was no significant association between specific CT findings and the diagnosis based on bronchoscopic examination. CONCLUSIONS No specific CT finding was identified as a predictor for either an antimicrobial response or for a corticosteroid response in this study. The presence of cavity formation and pleural effusion may predict a poor prognosis.


Biology of Blood and Marrow Transplantation | 2016

Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation.

Yu Akahoshi; Junya Kanda; Ayumi Gomyo; Jin Hayakawa; Yusuke Komiya; Naonori Harada; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Shun-ichi Kimura; Misato Kikuchi; Hideki Nakasone; Shinichi Kako; Yoshinobu Kanda

Secondary failure of platelet recovery (SFPR), a late decrease in the platelet count after primary platelet recovery that is not due to relapse or graft rejection, occasionally occurs after allogeneic hematopoietic stem cell transplantation (HSCT). The risk factors and impact of SFPR on transplantation outcomes are not well known in the clinical setting. Therefore, we retrospectively evaluated 184 adult patients who underwent their first allogeneic HSCT and achieved primary platelet recovery. The cumulative incidence of SFPR, defined as a decrease in the platelet count to below 20,000/µL for more than 7 days, was 12.2% at 3 years, with a median onset of 81 days (range, 39 to 729) after HSCT. Among patients who developed SFPR (n = 23), 19 (82.6%) showed recovery to a sustained platelet count of more than 20,000/µL without transfusion support, and the median duration of SFPR was 23 days (range, 7 to 1048 days). A multivariate analysis showed that in vivo T cell depletion (hazard ratio [HR], 6.92; 95% confidence interval [CI], 2.31 to 20.7; P < .001), grades II to IV acute graft-versus-host disease (HR, 3.99; 95% CI, 1.52 to 10.5; P = .005), and the use of ganciclovir or valganciclovir (HR, 2.86; 95% CI, 1.05 to 7.77; P = .039) were associated with an increased risk for SFPR. The occurrence of SFPR as a time-dependent covariate was significantly associated with inferior overall survival (HR, 2.29; 95% CI, 1.18 to 4.46; P = .015) in a multivariate analysis. These findings may help to improve the management and treatment strategy for SFPR.


Transplant Infectious Disease | 2014

Persistence of recipient-derived as well as donor-derived clones of cytomegalovirus pp65-specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation.

Kiriko Terasako-Saito; Hideki Nakasone; Yukie Tanaka; Rie Yamazaki; Miki Sato; Kana Sakamoto; Yuko Ishihara; Koji Kawamura; Yu Akahoshi; Jin Hayakawa; Hidenori Wada; Naonori Harada; Hirofumi Nakano; Kazuaki Kameda; Tomotaka Ugai; Ryoko Yamasaki; Masahiro Ashizawa; S.‐I. Kimura; Misato Kikuchi; Aki Tanihara; Junya Kanda; Shinichi Kako; Junji Nishida; Yoshinobu Kanda

Cytomegalovirus (CMV)‐specific CD8+ cytotoxic T lymphocytes (CMV‐CTLs) play a crucial role in preventing CMV disease. However, the actual in vivo dynamics of CMV‐CTL clones after allogeneic hematopoietic stem cell transplantation (alloHCT) are still unclear.


Hematological Oncology | 2018

Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome

Yu Akahoshi; Shun-ichi Kimura; Ayumi Gomyo; Jin Hayakawa; Masaharu Tamaki; Naonori Harada; Machiko Kusuda; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Misato Kikuchi; Hideki Nakasone; Shinichi Kako; Yoshinobu Kanda

Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long‐term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first allogenic HSCT with neutrophil engraftment. Of these 219 patients, 50 (22.8%) had DPR that was defined as relapse‐free survival at day 60 after HSCT without primary platelet recovery despite neutrophil engraftment. The results of a multivariate analysis showed that a high‐risk underlying disease (odds ratio [OR], 2.38; 95% confidence interval [CI], 1.04‐5.48; P = .041) and human leukocyte antigen–mismatched HSCT (OR, 2.63; 95% CI, 1.28‐5.43; P = .009) were associated with an increased risk of DPR. In univariate analyses, the occurrence of DPR was significantly associated with inferior overall survival, high nonrelapse mortality, and a low incidence of chronic graft‐versus‐host disease (GVHD), despite a comparable relapse rate. In multivariate analyses, DPR was associated with inferior overall survival (hazard ratio [HR], 2.00; 95% CI, 1.23‐3.27; P = .005) and a low incidence of chronic GVHD (HR, 0.42; 95% CI, 0.22‐0.78; P = .002). In conclusion, DPR was a strong predictor of shorter survival but also less frequent chronic GVHD.


Hematology | 2017

HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin).

Shinichi Kako; Yu Akahoshi; Naonori Harada; Hirofumi Nakano; Kazuaki Kameda; Tomotaka Ugai; Ryoko Yamasaki; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Masahiro Ashizawa; Kiriko Terasako-Saito; Shun-ichi Kimura; Misato Kikuchi; Hideki Nakasone; Rie Yamazaki; Junya Kanda; Yoshinobu Kanda

ABSTRACT Objectives: To clarify optimal strategies for human leukocyte antigen (HLA)-mismatched haploidentical hematopoietic stem cell transplantation (HSCT). Methods: Twelve patients who underwent HSCT from a haploidentical related donor using low-dose thymoglobulin were analyzed retrospectively. Thymoglobulin was added to conditioning regimens at 2.5 mg/kg/day for 2 days (days −4 and −3). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine and methotrexate. Results: The median age of the patients was 33 years. Six patients had previous allogeneic HSCT, and HSCT was performed in non-remission for nine patients. All patients but one, who died due to early infection, achieved neutrophil engraftment at a median of 17 days with complete donor-type chimerism. Acute and chronic GVHD were observed in six and five patients, respectively, but no patients died of GVHD-associated complication. No one developed cytomegalovirus disease, but Epstein–Barr virus-related lymphoproliferative disorder was observed in one patient. Long-term survival in remission without immunosuppressive agents are observed in two patients who underwent HSCT in remission, but the majority of patients who underwent HSCT in non-remission experienced disease progression. Conclusion: Haploidentical HSCT could be performed with thymoglobulin at 5 mg/kg, with the balance between GVHD and relapse rate. The dose reduction of thymoglobulin may be considered for advanced hematological malignancy.


Biology of Blood and Marrow Transplantation | 2017

Positive Cytotoxic Crossmatch Predicts Delayed Neutrophil Engraftment in Allogeneic Hematopoietic Cell Transplantation from HLA-Mismatched Related Donors

Kazuaki Kameda; Hideki Nakasone; Yusuke Komiya; Junya Kanda; Ayumi Gomyo; Jin Hayakawa; Yu Akahoshi; Masaharu Tamaki; Naonori Harada; Machiko Kusuda; Tomotaka Ugai; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Aki Tanihara; Hidenori Wada; Kiriko Terasako-Saito; Misato Kikuchi; Shun-ichi Kimura; Shinichi Kako; Yoshinobu Kanda

Although a positive cytotoxic crossmatch (XM) has been reported to predict graft failure, mainly in solid organ transplantations, its significance in allogeneic hematopoietic cell transplantation (HCT) remains to be elucidated. We retrospectively assessed the impact of positive XM on neutrophil engraftment in 41 patients who underwent HCT with an HLA-mismatched related donor. XM was positive in 22 patients. Six of these 22 patients were also positive for anti-HLA antibody, whereas only 1 was positive for donor-specific anti-HLA antibody. The cumulative incidence of engraftment at day +28 was 89.5% in patients with negative XM versus 59.1% in those with positive XM (P = .08). In particular, positive B cell warm XM was significantly associated with a lower probability of engraftment at day +28 (46.7% versus 88.5%; P = .04). In a multivariate analysis, both positive XM and positive B cell warm XM were significantly associated with delayed engraftment (hazard ratio [HR], .46; P = .02 and HR, .41; P = .01, respectively). There was no significant difference in the achievement of engraftment between those with and without detection of anti-HLA antibodies. In conclusion, positive XM might be associated with a delayed neutrophil engraftment after HCT from HLA-mismatched related donors.


Hematology | 2016

Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma.

Yuko Ishihara; Shun-ichi Kimura; Yu Akahoshi; Naonori Harada; Hirofumi Nakano; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Misato Kikuchi; Hideki Nakasone; Rie Yamazaki; Junya Kanda; Shinichi Kako; Aki Tanihara; Junji Nishida; Kensuke Usuki; Yoshinobu Kanda

Objectives: The D-index and the L-index, calculated as the area over the neutrophil and lymphocyte curves, respectively, reflect both the intensity and duration of cytopenia. We, retrospectively, investigated the impact of these indexes on pulmonary infection (PI) in induction chemotherapy for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Methods: We included 92 patients (ALL 83, LBL 9) from two institutions. We calculated the D-index and cumulative D-index until the development of PI (c-D-index), which enables real-time risk assessment for infection. We also calculated the L-index (35), defined as the area over the lymphocyte curve during lymphopenia (<700/µl) until day 35 and the cumulative-L-index until the development of PI (c-L-index). Results: Eight patients developed PI on day 20 (median). Two patients were strongly suspected to have bacterial pneumonia, and the others were suspected to have pulmonary fungal infection. The D-index and the L-index (35) in patients with PI were higher than those in patients without PI (7230 ± 4734 vs. 4519 ± 3416, P = 0.041 and 15 458 ± 5243 vs. 8920 ± 5901, P = 0.018), while the c-D-index and the c-L-index were not significantly different. Although the c-L-index did not have predictive value for PI, c-D-index, when treated as a dichotomous variable with a cutoff value of 5589 as determined by a receiver operating characteristic curve analysis, showed a significant difference between two groups (P = 0.045). This association became clearer when we focused on suspected pulmonary fungal infection. Discussion and conclusion: In induction chemotherapy for ALL/LBL, c-D-index with a cutoff value of 5589 might have predictive value for the development of PI.


Acta Haematologica | 2014

der(5;17)(p10;q10) Is a Recurrent But Rare Whole-Arm Translocation in Patients with Hematological Neoplasms: A Report of Three Cases

Masahiro Manabe; Junya Okita; Teruhito Takakuwa; Naonori Harada; Yasutaka Aoyama; Takeo Kumura; Tadanobu Ohta; Yoshio Furukawa; Atsuko Mugitani

We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5;17)(p10;q10), which results in the loss of 5q and 17p. Although deletions of 5q and 17p are recurrent abnormalities in hematological disease, only about 20 cases harboring der(5;17)(p10;q10) have been reported. We address the tumorigenesis and morphological characteristics of hematological malignancies involving der(5;17)(p10;q10), along with a review of the literature.

Collaboration


Dive into the Naonori Harada's collaboration.

Top Co-Authors

Avatar

Hidenori Wada

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Kazuaki Kameda

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Koji Kawamura

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Miki Sato

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Misato Kikuchi

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Shinichi Kako

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yu Akahoshi

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Yuko Ishihara

Jichi Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge